BioCentury
ARTICLE | Clinical News

Niraparib: Phase III started

May 12, 2014 7:00 AM UTC

Tesaro disclosed in its 1Q14 financial results that it began the open-label, U.S. Phase III BRAVO trial to compare 300 mg niraparib once daily in 21-day cycles vs. physician's choice of 4 standard-of-care chemotherapies in about 306 HER2-negative patients carrying germline BRCA1 or BRCA2 mutations who were previously treated with an anthracycline and a taxane. The product is also in the Phase III NOVA trial for platinum-sensitive, relapsed ovarian cancer. Tesaro has exclusive, worldwide rights to niraparib from Merck (see BioCentury, June 11, 2012). ...